ReWalk Robotics Ltd. (RWLK): history, ownership, mission, how it works & makes money

From earning FDA clearance in 2011 for the ReWalk Personal Exoskeleton to filing an IPO in 2014 seeking up to $58 million, ReWalk - now rebranded as Lifeward Ltd. - has evolved from a single-product exoskeleton pioneer into a diversified rehabilitation company that acquired AlterG for $19 million in 2023 and completed its name change effective September 13, 2024; publicly traded on NASDAQ as LFWD with a December 16, 2025 share price of $0.6215 and a market cap near $10.46 million, Lifeward markets a portfolio that includes ReWalk exoskeletons, the ReStore Exo-Suit, MyoCycle FES, and AlterG Anti-Gravity systems-devices that deliver powered hip/knee motion, soft-assist stroke rehabilitation, functional electrical stimulation, and unweighting technology respectively-sold via direct sales and leasing, supported by Medicare and insurer reimbursement efforts, strategic partnerships, and a push into cloud-connected hardware such as the April 2025 ReWalk 7; the company reported a record Q4 2024 revenue of $7.5 million and 85% annual growth to reach $25.7 million for 2024, projects $24-$26 million for 2025 while targeting non-GAAP operating expenses of $22-$23 million and aims for non-GAAP operating profitability in H2 2026 as it pursues improved reimbursement processing, expanded market applications, and integration of advanced sensing and AI into future systems.

ReWalk Robotics Ltd. (RWLK): Intro

• 2011 - FDA approval of the ReWalk Personal Exoskeleton for home and personal use by individuals with spinal cord injury (enabling upright ambulation).
• 2014 - Filed for an initial public offering on NASDAQ, aiming to raise up to $58 million.
• 2023 - Acquired AlterG (Anti-Gravity Systems) for $19 million, broadening rehabilitation product offerings.
• January 2024 - Rebranded as Lifeward Ltd., signaling expansion beyond exoskeletons into broader rehabilitation solutions.
• September 13, 2024 - Name change to Lifeward Ltd. finalized and became effective.
• April 2025 - Launched the ReWalk 7 personal exoskeleton featuring cloud connectivity and customizable walking speeds.

• Public company (formerly traded under ticker RWLK) that transitioned branding to Lifeward Ltd.; governance retained a public-company structure with a board and institutional investors prior to and after name change.
• Typical major holders include institutional investors and mutual funds (institutional ownership common among medtech small caps); executive and founder equity present for strategic alignment.

• Wearable robotic exoskeleton frame that supports lower limbs and hips, driven by battery-powered motors at hip and knee joints.
• Onboard sensors and control algorithms detect user intent and gait phase to coordinate motor actuation and balance assistance.
• User interface allows clinician/programmer tuning; ReWalk 7 adds cloud connectivity for remote firmware updates, data capture, and customizable walking-speed profiles.
• Therapy integration: exoskeletons used in clinical rehabilitation settings and personal/home use to promote mobility, cardiovascular activity, and secondary health benefits.

• Device sales - one-time sales of personal and clinical exoskeleton units (higher ASPs per unit relative to typical durable medical equipment).
• Service, training, and maintenance - clinical training for therapists, patient fitting, warranty and post-sale service contracts.
• Leasing and rental programs - short-term rentals to clinics and rehabilitation centers; longer-term leasing options for patients and institutions.
• Complementary product sales - acquisition of AlterG expanded recurring-revenue opportunities from anti-gravity treadmills and rehabilitation device consumables.
• Data and software services - cloud-enabled telemetrics, remote monitoring, and software subscriptions associated with ReWalk 7 (new recurring revenue stream).

• Target markets: spinal cord injury patients, neurological and orthopedic rehabilitation clinics, veteran and insurance-funded programs.
• Value proposition: restore upright mobility, improve secondary health outcomes, enable intensive gait therapy; new SaaS and device bundle model after AlterG acquisition and ReWalk 7 launch.
• Competitive landscape: specialized medical robotics and rehabilitation equipment vendors; differentiation through regulatory approvals, clinical evidence, and integrated device-software services.

ReWalk Robotics Ltd. (RWLK): History

• Founded as a pioneer in wearable robotic exoskeletons for individuals with spinal cord injury and neurological disorders.
• Expanded from clinical and rehabilitation markets into consumer and institutional channels via strategic partnerships and acquisitions.
• Post-acquisition integration and leadership realignment emphasized scaling global sales and go-to-market capabilities.

Ownership Structure

• ReWalk Robotics Ltd. is publicly traded on the NASDAQ under ticker RWLK.
• As of December 16, 2025, the stock price is $0.6215 per share with an approximate market capitalization of $10.46 million.
• The shareholder base is diversified: institutional investors, individual shareholders, and company insiders.
• In August 2023, ReWalk acquired AlterG for $19 million, integrating AlterG into ReWalk's operations.
• The acquisition was financed entirely from ReWalk's cash reserves, leaving the company with a debt-free balance sheet post-transaction.
• Charles Remsberg, formerly CEO of AlterG, now leads the combined global sales organization as Chief Sales Officer.

How It Works

How It Makes Money

• Direct device sales to hospitals, rehabilitation centers and private-pay consumers (capital equipment revenue).
• Recurring revenue from service contracts, maintenance, software updates and consumables.
• Training and clinical onboarding fees for healthcare providers and centers.
• Partnerships and channel distribution agreements that broaden market reach and generate reseller revenue streams.

ReWalk Robotics Ltd. (RWLK): Ownership Structure

• ReWalk's mission is to deliver life-changing solutions that revolutionize rehabilitation and empower individuals with physical limitations to pursue their passions.
• The company is committed to pioneering innovative technology to elevate the standard of care in overcoming physical limitations and disabilities.
• ReWalk's portfolio includes the ReWalk Exoskeleton, ReStore Exo-Suit, MyoCycle FES System, and AlterG Anti-Gravity systems.
• The company emphasizes a patient-centric approach, focusing on delivering functional and health benefits in both clinical settings and the community.
• ReWalk values collaboration, integrating expertise from various disciplines to drive innovation in rehabilitation technologies.
• The company is dedicated to continuous improvement, striving to enhance the quality of life for individuals with physical disabilities through advanced solutions.

• Founded in 2001; early clinical prototypes demonstrated feasibility of motorized exoskeleton-assisted gait for people with spinal cord injury.
• FDA clearance milestones: first personal exoskeleton clearance (Class II, ReWalk Personal) for home and community use; subsequent clearances for rehabilitation versions and components.
• Public listing: Nasdaq IPO in 2014 to accelerate commercialization and scale manufacturing and distribution.

• ReWalk Exoskeleton: battery-powered, wearable robotic suit with motorized hip and knee joints, onboard sensors, and a motion controller that detects user-initiated movements to enable upright walking.
• ReStore Exo-Suit: lightweight soft exosuit focused on gait training and rehabilitation in clinical settings (augments biological muscles rather than replacing joints).
• MyoCycle FES System: arm and leg functional electrical stimulation systems for neuromuscular re-education and exercise.
• AlterG Anti-Gravity systems: offloading treadmills that enable body-weight-supported gait training (often used alongside exoskeletons in clinics).

• Direct sales of devices to rehabilitation clinics, hospitals, and private users.
• Recurring revenue from service contracts, consumables, training programs, and software upgrades.
• Reimbursement-dependent pricing: hospital and outpatient use supported by payer coverage in select markets, influencing adoption rates.
• Partnerships and distributor agreements to expand geographic reach (EMEA, North America, APAC).

• Revenue growth is driven by clinic adoption, geographic expansion, and increased reimbursement recognition; margins constrained by manufacturing scale and install/support costs.
• Investment focuses on product development (lighter, more efficient devices), evidence-generation (clinical trials demonstrating functional and health benefits), and expanding service/revenue streams.

ReWalk Robotics Ltd. (RWLK): Mission and Values

• The ReWalk Exoskeleton is a rigid, powered wearable system that provides motorized hip and knee joint motion to enable individuals with spinal cord injuries (SCI) to stand, walk and sit. Sensors, onboard processors and battery-powered motors coordinate gait phases and balance assistance while the user controls initiation and stopping via a wrist-mounted controller or remote.
• The ReStore Exo-Suit is a lightweight, textile-based soft exosuit designed for post-stroke rehabilitation. It applies assistive forces to the ankle and/or lower limb during gait training to improve symmetry, walking speed and endurance during clinical therapy sessions.
• The MyoCycle FES System uses functional electrical stimulation (FES) to activate paralyzed or weakened muscles (typically lower-limb) in coordinated patterns, enabling cycling motion to strengthen muscles, improve cardiovascular health and reduce secondary complications of immobility.
• The AlterG Anti-Gravity systems (often distributed by rehabilitation-focused companies) employ differential air-pressure unweighting in a treadmill enclosure to reduce effective body weight by precise increments, lowering joint impact and enabling earlier, longer or higher-intensity gait training.
• Lifeward and ReWalk devices are controlled via user-friendly interfaces-wrist-mounted remotes, clinician touchscreens or tablet UIs-allowing intuitive operation, mode selection, and customizable program adjustment by therapists or trained caregivers.
• Across systems, adjustable settings, modular components and therapy programs enable adaptation to individual user anthropometrics, injury level, therapy goals and progression milestones.

• Typical walking speeds with the ReWalk personal exoskeleton range from approximately 0.2 to 0.6 m/s depending on user conditioning and training; therapy-mode speeds can vary based on clinician programming.
• Clinical studies of soft exosuits and FES systems report improvements in gait symmetry, step length and 6-minute walk distance after multi-week training protocols; individual outcomes depend on stroke chronicity and therapy intensity.
• AlterG unweighting commonly allows 10-80% body-weight reduction ranges for progressive gait or treadmill training, enabling earlier ambulation and higher repetition therapy with reduced pain or joint stress.

• Founding year: 2001; Nasdaq IPO: 2014 (ticker: RWLK).
• Units sold since commercialization: several hundred personal and clinical systems (company disclosures historically referenced mid-hundreds of units).
• Annual revenue (historical range): public filings in prior years showed revenues in the low single-digit to low double-digit millions USD per year (variable by year and product mix).
• Gross margin dynamics: higher margins on software, service and consumables; capital-intensive cost structure for R&D and production of hardware platforms.

• Primary customers: rehabilitation hospitals, private therapy clinics, government-funded health systems and motivated individuals pursuing personal exoskeleton ownership.
• Reimbursement: coverage policies vary widely-some institutions secure coverage for in-clinic therapy devices; personal-use reimbursement is limited and often requires appeals, case-by-case decisions or charitable funding.
• Market size drivers: incidence/prevalence of spinal cord injury and stroke (stroke affects tens of millions globally each year with many survivors needing rehabilitation), aging population, and increased adoption of technology-enabled rehab.

• Ownership: historically a publicly traded company (RWLK) with institutional investors, management and founder stakeholders; ownership composition evolved with public markets and private placements.
• Partnerships: distribution and clinical partnerships with rehabilitation providers, research collaborations with academic medical centers, and channel relationships to expand geographic reach.
• Strategic focus: expand clinical evidence base, increase reimbursement adoption, scale service and training operations, and diversify product portfolio toward lighter, therapy-focused devices like soft exo-suits and FES systems.

• Training and clinical protocols are essential-typical therapy courses last weeks to months with progressive adjustments and objective outcome tracking (e.g., 6MWT, TUG, gait speed).
• Battery life and portability: personal exoskeletons use rechargeable battery packs enabling several hours of intermittent use; maintenance and component replacement are part of ongoing cost of ownership.
• Regulatory clearances: devices obtain region-specific approvals (e.g., FDA 510(k) or CE marking) for specified indications, influencing market access and claims.

ReWalk Robotics Ltd. (RWLK): How It Works

• Device sales - one-time sales of systems such as the ReWalk Exoskeleton, ReStore Exo-Suit, MyoCycle FES System and, following acquisition activity, AlterG Anti-Gravity systems; unit prices vary by model and configuration.
• Leasing and rental programs - short- and long-term lease options for clinics, hospitals and rehab centers to lower initial acquisition costs and accelerate adoption.
• Service, maintenance and spare parts - recurring revenue from service contracts, training, software updates and replacement components.
• Reimbursement and payor relationships - pursuing Medicare and private insurer coverage to enable third-party payment for devices and supervised therapy sessions, increasing addressable market.
• Strategic partnerships and distribution agreements - co-development, licensing and reseller partnerships to expand market penetration into new geographies and clinical segments.
• Market expansion and new applications - targeting broader clinical uses (stroke, multiple sclerosis, spinal cord injury) and non-clinical channels (sports recovery, wellness) to diversify revenue.

• Direct sales to rehabilitation centers and hospitals remain a primary channel, supported by targeted clinical evidence demonstrating functional gains for patients with spinal cord injury and other neurological conditions.
• Leasing programs and pay-per-use models reduce adoption barriers and create recurring revenue streams that complement device sales.
• Pursuit of Medicare and commercial insurance reimbursement is a strategic priority - coverage agreements or positive local reimbursement decisions materially affect uptake in major markets.
• Acquisitions and partnerships (e.g., expansion via AlterG or similar strategic bets) broaden the product portfolio and enable cross-selling into orthopedics, sports medicine and general rehabilitation, increasing potential revenue per customer.
• Clinical collaborations and trials help produce published outcomes that support reimbursement submissions and drive clinician adoption.

• Expand direct sales in key geographies while scaling distributor networks in markets with strong hospital and clinic demand.
• Grow leasing penetration to convert single large capital expenditures into multi-year recurring revenue.
• Negotiate and document reimbursement pathways with Medicare and private insurers; secure coding, coverage and payment where possible.
• Invest in adjacent product lines and acquired platforms (e.g., anti‑gravity treadmills) to capture a broader share of rehabilitation budgets.
• Drive service and consumables attach rates to increase lifetime customer value.

ReWalk Robotics Ltd. (RWLK): How It Makes Money

• Direct device sales to hospitals, rehabilitation centers, and individual consumers (where reimbursed).
• Consumables, service contracts, software subscriptions, training and maintenance agreements.
• Reimbursement capture via Medicare and private payors-critical to unit economics and end-user affordability.
• R&D collaborations and potential licensing of sensing/AI technologies in future models.

• Cost discipline-reducing non-GAAP operating expenses to the $22-23M range in 2025 to narrow losses and support path to profitability.
• Reimbursement optimization-working with Medicare administrative contractors to accelerate claims processing and increase adoption.
• Product innovation-integrating advanced sensing technologies and AI to create higher-margin software-enabled features and subscription opportunities.
• Commercial execution-expanding sales channels and aftercare services to increase recurring revenue per unit.